Drug Name Zyban

On 23 October 2008, the European Medicines Agency (EMEA) issued a press release stating its Committee for Medical Products for Human Use (CHMP) had concluded the benefits of Acomplia no longer outweighed its risks, and subsequently recommended the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating the drug had been suspended. Approval of the drug was officially withdrawn by the EMEA on 16 January 2009.
CELEBREX is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

 

Canine broad-spectrum antibiotic in oral dosage form: oral tablets. Combines broad-spectrum antibiotic activity of amoxicillin with unique b-lactamase inhibiting effect of clavulanic acid, which extends the antibacterial spectrum to b-lactamase-producing and non-b-lactamase-producing organisms.
Findings from a recent study, she said, suggest that the 50 gram glucose challenge test, a test used to screen for gestational diabetes in pregnancy, may represent a promising alternative to HbA1c as a screening test for diabetes or prediabetes (Phillips et al. Diabetologia. 2009;52:1798-1807) because it has been shown to be accurate and can be readily performed during office visits at any time of the day and without a prior fast.